BAY 12-9566 will be compared to placebo in terms of safety, tolerability and efficacy in a 3-month, multicenter, double-blind, randomized study of patients with symptomatic osteoarthritis (OA) of the knee. This investigational drug is a novel inhibitor of stromelysins which are involved in the degradation of structural proteins felt to be central to the pathogenesis of OA.
Showing the most recent 10 out of 395 publications